Rho Gtpase Pathway

Researchers tracked 34 cutaneous T-cell lymphoma patients using comprehensive multi-omics and serial sampling, creating the first single-cell resolution map of how cancer evolves to escape treatment. The study identified specific recurrent mutations — including STAT3 D661Y driving HDAC inhibitor resistance and EZH2 alterations targetable with existing drugs — providing a roadmap for genome-guided therapeutic decisions and improved disease monitoring.